Pfizer, Blackstone Agree to Up to $1.5 Billion in Obesity Drug Funding

MT newswire2026/11/11 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

05:07 PM EST, 11/11/2026 (MT Newswires) -- Pfizer (PFE) and Blackstone Life Sciences agreed to a funding arrangement under which Blackstone-managed funds will provide up to $1.5 billion through 2028 for the development of Pfizer's investigational obesity drug berobenatide, the companies said late Wednesday. Blackstone will be eligible for milestone-based payments, subject to US regulatory approval of monthly injectable dosing for chronic weight management and the achievement of commercial sales milestones, the companies said. Berobenatide is a potential monthly GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions, the companies said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to Bloomberg, CoreWeave is seeking to refinance at least 4 billion USD through an investment-grade loan, led by Morgan Stanley and Mitsubishi UFJ, with a syndication roadshow expected to start as soon as next week. This financing continues the structure of using Nvidia chips and customer contracts as collateral, with the yield on the issuance anticipated to be around 7% to 7.5%, much lower than its junk bond yield. Following the news, CoreWeave's shares fell nearly 5.8% after hours.

华尔街见闻•2026/11/11 23:46